Mayer Brown JSM and O’Melveny & Myers have advised on biomedical materials maker Shanghai Haohai Biological Technology Co’s $302 million IPO on the Hong Kong Stock Exchange.

At HK$59 per share, Shanghai Haohai priced its offering at the top of its range. The listing took place on April 30.

Shanghai Haohai will use the proceeds to pay for new production lines, production equipment and acquisitions, the company said.

Hong Kong partner Gigi Woo led the O’Melveny team that advised Shanghai Haohai, with support from Beijing partner Ke Geng.

Mayer Brown Hong Kong partners James Fong and Jason Elder represented UBS Securities as the sole sponsor, and UBS, CMB International Capital and CCB International Capital as the underwriters of the offering. 

Grandall Law Firm and Grandway Law Offices provided PRC legal advice to Shanghai Haohai and the underwriters, respectively.